Patients who received M-V were more likely to have AKI (16% compared to 8%) but this did not reach statistical significance.
← all excerpts
1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
1
—
—